ESMO VIRTUAL PRECEPTORSHIP PROGRAMME
IMMUNO-ONCOLOGY
From the essentials of tumour immunology to clinical application
18-19 November 2020

CO-CHAIRS:
John B.A.G. Haanen, Netherlands
Ross A. Soo, Singapore

SPEAKERS:
Cheng Ean Chee, Singapore
Jayesh Desai, Australia
Boon Cher Goh, Singapore
Alena Gros, Spain
Ravindran Kanesvaran, Singapore
Soo Chin Lee, Singapore
Brigette Ma, Hong Kong
Kenneth John O’Byrne, Australia
Solange Peters, Switzerland
Michele Teng, Australia
Baiyan Wang, China

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

All timings are to be considered GMT+8

Wednesday, 18 November 2020

| 15:00-15:05  | Welcome | John B.A.G. Haanen, NL  
| 5’           |         | Ross A. Soo, SG |
| 15:05-15:45  | SESSION 1 | Chair/Moderator: 
| 40’          | Introduction | John B.A.G. Haanen, NL  
|              |           | Ross A. Soo, SG |
| 15’          | Principles of tumour immunology: Explaining cellular immunity and immune surveillance | Michele Teng, AU |
| 15’          | Principles of cancer immunotherapy | Alena Gros, ES |
| 10’          | Discussion | Faculty |
15:45-16:40
SESSION 2
Recent advances with ICPI: Results in approved/unapproved indication – part 1
Chair/Moderator: John B.A.G. Haanen, NL
Ross A. Soo, SG

15’ Melanoma advanced and adjuvant
John B.A.G. Haanen, NL

15’ Non-Small-Cell Lung Cancer
Ross A. Soo, SG

15’ Gynaecological malignancies and breast cancer
Soo Chin Lee, SG

10’ Discussion
Faculty

16:40-16:50
Break

16:50-18:00
SESSION 3
Clinical issues
Chair/Moderator: Ross A. Soo, SG

15’ Assessment of efficacy
Kenneth John O’Byrne, AU

15’ Immune related toxicities and management
John B.A.G. Haanen, NL

15’ Biomarkers: PD-L1 and beyond
Boon Cher Goh, SG

15’ Cost of immuno-oncology treatment
Solange Peters, CH

10’ Discussion
Faculty

18:00-18:40
SESSION 4
Audience cases
Chair/Moderator: John B.A.G. Haanen, NL
Ross A. Soo, SG

40’ Participants clinical case discussion (4x10’)
Faculty

Thursday, 19 November 2020

15:00-15:55
SESSION 5
Recent advances with ICPI: Results in approved/unapproved indication – part 2
Chair/Moderator: John B.A.G. Haanen, NL
Ross A. Soo, SG

15’ Oesophageal, gastric and colorectal cancer
Jayesh Desai, AU

15’ Hepatocellular carcinoma (HCC)
Cheng Ean Chee, SG

15’ Head and neck cancer
Brigette Ma, HK

10’ Discussion
Faculty

15:55-16:20
SESSION 6
Recent advances with ICPI: Results in approved/unapproved indication – part 3
Chair/Moderator: John B.A.G. Haanen, NL
Ross A. Soo, SG

15’ Advanced urinary cancer (renal and bladder)
Ravindran Kanesvaran, SG

10’ Discussion
Faculty

16:20-16:30
Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Moderator</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-17:50</td>
<td>SESSION 7</td>
<td>John B.A.G. Haanen, NL Ross A. Soo, SG</td>
<td>Participants clinical case discussion (8x10')</td>
</tr>
<tr>
<td>17:50-18:15</td>
<td>SESSION 8</td>
<td>John B.A.G. Haanen, NL Ross A. Soo, SG</td>
<td>CAR T-Cell therapy</td>
</tr>
<tr>
<td>18:15-18:20</td>
<td>Closure and farewell</td>
<td>John B.A.G. Haanen, NL Ross A. Soo, SG</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion.